The evolution of prescription and the costs of antidepressants in a primary care area (1996-2001);La evolución de la prescripción y los costes de los antidepresivos en un área de Atención Primaria (1996-2001)

Semergen

Volumn 31, Issue 10, 2005, Pages 456-461

  Ortiz Lobo, A ^a   Lozano Serrano, C ^b   Fernandez Jimenez G ^c  

^a Centro de Salud Mental de Salamanca   (Spain)

^b Centro de Salud Mental de Torrejon   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

antidepressants; drug cost; prescription; Primary Health Care; work discapacity

Indexed keywords

EID: 33746357403     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/S1138-3593(05)72970-1     Document Type: Article

References (31)

1. Paykel E.S., and Priest R.G. Recognition and management of depresión in general practice: consensus statement. BMJ 305 (1992) 1198-1202
2. Donoghue J.M., and Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. Br J Psychiatry 168 (1996) 164-168
3. Lawrenson R.A., Tyer F., and Farmer R.D. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Afect Disords 59 (2000) 149-157
4. Ruiz-Doblado S., and Caraballo-Camacho M. Pharmacoepidemiological patterns of antidepressant prescribing in primary care in rural Spain (1995-1999). Int J Soc Psychiatry 48 1 (2002) 71-77
5. Alonso M.P., De Abajo F.J., Martínez J.J., Montero D., Martín-Serrano G., and Madurga M. Evolución del consumo de antidepresivos en España. Impacto de los inhibidores selectivos de la recaptación de serotonina. Med Clin (Barc) 108 (1997) 161-166
6. Díaz Madero A., López Ferreras M.T., Ruiz-Clavijo Díez M., and Vargas Aragón M.L. Evolución del consumo de antidepresivos en el área de Zamora desde 1996 a 1999. Aten Primaria 28 (2001) 333-339
7. De las Cuevas C., Sanz E.J., and De la Fuente J.A. Variations in antidepressant prescribing practice: clinical need or market influences?. Pharmacoepidemiol Drug Saf 11 (2002) 515-522
8. Hemels M.E., Koren G., and Einarson T.R. Increased Use of Antidepressants in Canada:1981-2000. Ann Pharmacother 36 (2002) 1375-1379
9. Barbui C., Campomori A., D'Avanzo B., Negri E., et al. Antideressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Epidemiol 34 (1999) 152-156
10. McManus P., Mant A., Mitchell P.B., Montgomery W.S., Marley J., and Auland M.E. Recent trends in the use of antidepressant drugs in Australia, 1990-1998. MJA 173 (2000) 458-461
11. Middleton N., Gunnell D., Whitley E., et al. Secular trends in antidepressant prescribing in the UK, 1975-1998. J Public Health Med 23 (2001) 262-267
12. Harm W.J., et al. Antidepressant prescription for depression in general practice in tha Netherlands Pharm World Sci 23 (2001) 46-49
13. Sclar D.A., RobiNson L.M., Skaer T.L., and Galin R.S. Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990-1995. Clinical Therapeutics 20 (1988) 871-884
14. Pincus H.A., Tanielian M.A., Marcus S.C., et al. Prescribing trends in psychotropic medications. JAMA 279 (1998) 526-531
15. Gury M. IMS reports 12 percent growth in 2001 audited global pharmaceuticals sales. IMS Health 2002 http://www.ims-global com/insight/news_story/0103/news_story_010314.htm
16. Rosholm J.V., Gram L.F., Isaccsson G., Hallas J., and Bergman V. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 52 (1997) 205-209
17. Johnson R.E., McFarland B.M., and Nichols G.A. Changing patterns of antidepressant use and costs in a health maintance organisation. Pharmacoeconomics 11 (1997) 274-283
18. Frank L., Revicki D.A., Sorensesn S.V., and Shih Y.C. The economics of Selective Serotonin Reuptake Inhibitors in depression. A critical review. CNS Drugs 15 (2001) 59-83
19. Zito J.M., Sater D.J., Dos Reis S., et al. Rising prevalence of antidepressants among US youths. Pediatrics 109 (2002) 721-727
20. Cervera Cansino P. Difusión de los nuevos medicamentos y su incorporación a la práctica clínica. In: Meneu R., and Peiró S. (Eds). Elementos para la gestión de la prescripción y la prestación farmacéutica (2004), Masson, Barcelona
21. Gutiérrez J.F., Franco M.A., Gascón J., and Porras-Chavarino A. Tratamiento de los trastornos depresivos en atención primaria: efectividad y tolerancia a la sertralina. SEMERGEN 28 (2002) 73-79
22. Pini S., and Tansella M. Detección y manejo de la enfermedad mental en los centros de atención primaria. In: Vázquez-Barquero J.L. (Ed). Psiquiatría en atención primaria (1998), Grupo Aula Médica, Madrid
23. Ortiz Lobo A. Consultas sin patología en un centro de salud mental. Tesis doctoral (2004), Universidad Autónoma de Madrid, Madrid
24. Murphy J.M., Laird N.M., Monson R.R., et al. A 40-year perspective on the prevalence of depression. The Stirling County Study Arch. Gen Psychiatry 57 (2000) 209-215
25. Mata Ruiz I., and Ortiz Lobo A. Industria farmacéutica y psiquiatría. Rev Asoc Esp Neuropsiq 86 (2003) 49-71
26. Double D. The limits of psychiatry. BMJ 324 (2002) 900-904
27. Márquez S., and Meneu R. La medicalización de la vida y sus protagonistas. Gestión Clínica y Sanitaria 5 (2003) 47-53
28. Jick S.S., Dean A.D., and Jick H. Antidepressants and suicide. BMJ 310 (1995) 215-218
29. Levi F., La Vecchia C., and Saraceno B. Global suicide rates. European J Public Health 13 (2003) 97-98
30. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72 (2003) 71-79
31. Moncrieff J., and Pomerlau J. Trends in sickness benefits in Great Britain and the contribution of mental disorders. J Public Health Med 22 (2000) 59-67